 |
Pulmonary Arterial Hypertension (PAH): Clinical Applications for the Cardiologist Today and Tomorrow CME Michael J. Landzberg, MD; Robyn J. Barst, MD, FAHA; Raymond L. Benza, MD; Michael A. Mathier, MD, FACC; Vallerie V. McLaughlin, MD, FACC, FAHA DisclosuresRelease Date: January 16, 2007; Valid for credit through January 16, 2008 | Physicians - maximum of 2.0 AMA PRA Category 1 Credit(s)™ for physicians | | This CME activity is based on transcripts and slides of presentations as delivered by the faculty at the "Pulmonary Arterial Hypertension (PAH): Clinical Applications for the Cardiologist Today and Tomorrow" symposium held at the Hilton Chicago in Illinois on November 13, 2006. |
| Contents of This CME Activity | |
| This activity is offered in two formats. Please choose one of the versions:
Slides and Audio Version
Requires Flash 7
Download Latest Flash Player
--OR--
Slides with transcript:
- The Role of the Cardiologist in PAH
by Michael A. Mathier, MD, FACC
Summary
Knowledge of the Disease
High Index of Suspicion
Interpretation of Screening Studies
Performance and Interpretation of Right Heart Catheterization
Treatment Commensurate With Ability and Experience
Diagnosis and Management of Right Ventricular Failure
Conclusions
- Diagnosing PAH: Where Do We Go From Here?
by Raymond L. Benza, MD
Nomenclature
The Importance of Classification
Diagnosing PAH
Diagnostic Algorithm
Ruling Out Left-Sided Heart Disease
Ruling Out CHD
Ruling Out CTD and HIV
Ruling Out Chronic Thromboembolic Disease
Ruling Out Lung Disease
Establishing a Prognosis
- Treatment Strategies for PAH in CHD
by Michael J. Landzberg, MD
Overview
Prevalence of CHD
Classification of CHD
Shunts
Etiology of CHD
Types of PAH in CHD
Eisenmenger Complex
Palliative Treatments for Eisenmenger Syndrome
Bosentan as a Treatment for Eisenmenger Syndrome
Summary
- Sickle Cell and HIV: Patients at Risk for PAH
by Robyn J. Barst, MD, FAHA
Classification of Pulmonary Hypertension
HIV and PAH: Background
Treatment With Epoprostenol
Treatment With Endothelin Receptor Antagonists
Treatment With Sildenafil
PAH Related to HIV: Conclusions
Sickle Cell Disease and PAH: Background
Tricuspid Regurgitation Velocity and Sickle Cell Disease
Sickle Cell Disease and Thalassemia
Disease Parameters in Sickle Cell Disease and PAH
Treating Hemolysis-Associated Pulmonary Hypertension
Epoprostenol and Sildenafil
Endothelin Receptor Antagonists
PAH Related to SCD: Conclusions
- Applying Lessons of Heart Failure in PAH
by Vallerie V. McLaughlin, MD, FACC, FAHA
Lessons From Heart Failure Trials
Goals of Pulmonary Hypertension Treatment
Calcium Channel Blockers
Targets for PAH Therapies
Prostacyclins
Bosentan
Sildenafil
Optimal Treatment Strategy for PAH
Combination Therapy in PAH
Conclusions
- Question and Answer Period
by Michael A. Mathier, MD, FACC, Raymond L. Benza, MD, Michael J. Landzberg, MD, Robyn J. Barst, MD, FAHA, and Vallerie V. McLaughlin, MD, FACC, FAHA
- Go to Test Questions
Take this program with you! Download this Web Conference as an MP3 and load it onto your iPod or other portable audio player for audio CME on-the-go. (Right-click and select "Save Target As…" to download) These educational activities, certified by accredited providers, were not prepared by Medscape's editors, but are made available on our site as a service to our audience. Authors are routinely instructed by the provider to disclose significant financial relationships and mention of investigational drugs and unapproved indications. Medscape has received a fee for posting these activities. Direct questions or comments to: CME@webmd.net. |
| Legal Disclaimer | |
| The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. |
Copyright © 2007 Medical Education Resources.
|
|
 |
Medical Education Resources is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians.
Medical Education Resources designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Contact This Provider
|
|
